Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 21,167 Shares

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri bought 21,167 shares of Nuvectis Pharma stock in a transaction dated Monday, May 12th. The stock was purchased at an average cost of $8.11 per share, for a total transaction of $171,664.37. Following the purchase, the insider now owns 2,942,761 shares of the company’s stock, valued at approximately $23,865,791.71. This trade represents a 0.72% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Thursday, May 8th, Marlio Charles Mosseri bought 2,650 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $8.65 per share, for a total transaction of $22,922.50.
• On Tuesday, May 6th, Marlio Charles Mosseri purchased 12,444 shares of Nuvectis Pharma stock. The stock was purchased at an average price of $8.59 per share, for a total transaction of $106,893.96.

Nuvectis Pharma Trading Up 0.5%

Shares of NVCT opened at $8.43 on Wednesday. Nuvectis Pharma, Inc. has a 12-month low of $4.44 and a 12-month high of $11.80. The firm has a 50-day moving average price of $9.03 and a 200 day moving average price of $7.20. The firm has a market capitalization of $199.24 million, a P/E ratio of -7.27 and a beta of -0.11.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.03. Equities research analysts predict that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nuvectis Pharma

A number of hedge funds have recently modified their holdings of the business. Austin Wealth Management LLC purchased a new position in shares of Nuvectis Pharma during the first quarter worth approximately $393,000. Iridian Asset Management LLC CT purchased a new position in Nuvectis Pharma in the 1st quarter valued at $2,481,000. Oppenheimer & Co. Inc. grew its position in Nuvectis Pharma by 64.0% in the 1st quarter. Oppenheimer & Co. Inc. now owns 41,000 shares of the company’s stock valued at $401,000 after buying an additional 16,000 shares during the last quarter. Baldwin Wealth Partners LLC MA grew its position in Nuvectis Pharma by 0.7% in the 1st quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company’s stock valued at $3,502,000 after buying an additional 2,500 shares during the last quarter. Finally, Blue Zone Wealth Advisors LLC purchased a new position in Nuvectis Pharma in the 1st quarter valued at $102,000. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on NVCT shares. Laidlaw started coverage on shares of Nuvectis Pharma in a research report on Monday, March 17th. They issued a “buy” rating and a $19.00 price objective for the company. Maxim Group assumed coverage on shares of Nuvectis Pharma in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $17.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price target (up from $11.00) on shares of Nuvectis Pharma in a research report on Wednesday, April 30th.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.